

- **Name:** Eun-Kee Song
  
- **Current Position:** Professor in Division of Hematology/Medical Oncology of Chonbuk National University Medical School
  
- **Country:** Republic of Korea
  
- **Educational Background:**
  - B.S. : 1993 ~ 1999, Chonbuk National University Medical School
  - M.S. : 2001 ~ 2003, Chonbuk National University Medical School
  - Ph.D. : 2005 ~ 2008, Chonnam National University Medical School
  
- **Professional Experience:**
  - 2000 ~ 2004 : Residency of Internal medicine in Chonbuk National University Hospital
  - 2004 ~ 2005: Fellowship in Division of Hematology/Oncology of Seoul National University Hospital
  - 2005 ~ 2016: Assistant & Associate Professor in Division of Hematology / Oncology, Department of Internal Medicine of Chonbuk National University Medical School
  - 2012 ~ 2013: Visiting Scholar in University of Colorado Denver
  - 2016 ~ Present: Professor in Division of Hematology / Oncology, Department of Internal Medicine of Chonbuk National University Medical School
  - 2014 ~ Present: Head of Division of Medical Oncology & Hematology, Department of Internal Medicine, Chonbuk National University Hospital
  
- **Professional Organizations:**
  - 2004 ~ Present : Life member of The Korean Association of Internal Medicine (KAIM)
  - 2006 ~ Present : Board member of Korean Society of Medical Oncology (KSMO)
  - 2007 ~ Present : Active full member of Korean Cancer Study Group (KCSG) / Member of Protocol Review Committee (PRC)
  - 2008 ~ Present : Active full member of American Society of Clinical Oncology (ASCO)
  - 2012 ~ Present : Active member of American Association for Cancer Research (AACR)

- 2016 ~ Present : Consultant of Health Insurance Review & Assessment Service
- 2016 ~ Present: Chairman of Institutional Review Board in Chonbuk National University Hospital

• **Main Scientific Publications:**

1. Efficacy and safety of FOLFIRI regimen in elderly versus nonelderly patients with metastatic colorectal or gastric cancer. *Oncologist*. 2017;22(3):293-303.
2. Evaluation of the efficacy of dasatinib, a Src/Alb inhibitor, in colorectal cancer cell lines and explant mouse model. *PLoS One*. 2017;12(11):e0187173.
3. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). *Gastric Cancer*. 2018;21(5):819-30.
4. A randomized, double-blind, placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study. *Cancer Res Treat*. 2019;51(1):90-7.
5. Attitudes toward early palliative care in cancer patients and caregivers: a Korean nationwide survey. *Cancer Med*. 2018;7(5):1784-93.
6. Priorities of a "good death" according to cancer patients, their family caregivers, physicians, and the general population: a nationwide survey. *Support Care Cancer*. 2018;26(10):3479-88.
7. Feasibility and accessibility of electronic patient-reported outcome measures using a smartphone during routine chemotherapy: a pilot study. *Support Care Cancer*. 2018;26(11):3721-8.
8. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial. *Korean J Intern Med*. 2018 [Epub ahead of print]
9. Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis. *Medicine (Baltimore)*. 2018;97(21):e10778.
10. Comparison of attitudes toward five end-of-life care interventions (active pain control, withdrawal of futile life-sustained treatment, passive euthanasia, active euthanasia and physician-assisted suicide): a multicentered cross-sectional survey of Korean patients with cancer, their family caregivers, physicians and the general Korean population. *BMJ Open*. 2018;8(9):e020519.
11. A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. *Gastric Cancer*. 2019 [Epub ahead of print]